<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39414789</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2059-0105</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>NPJ vaccines</Title><ISOAbbreviation>NPJ Vaccines</ISOAbbreviation></Journal><ArticleTitle>A multiantigenic Orf virus-based vaccine efficiently protects hamsters and nonhuman primates against SARS-CoV-2.</ArticleTitle><Pagination><StartPage>191</StartPage><MedlinePgn>191</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">191</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41541-024-00981-2</ELocationID><Abstract><AbstractText>Among the common strategies to design next-generation COVID-19 vaccines is broadening the antigenic repertoire thereby aiming to increase efficacy against emerging variants of concern (VoC). This study describes a new Orf virus-based vector (ORFV) platform to design a multiantigenic vaccine targeting SARS-CoV-2 spike and nucleocapsid antigens. Vaccine candidates were engineered, either expressing spike protein (ORFV-S) alone or co-expressing nucleocapsid protein (ORFV-S/N). Mono- and multiantigenic vaccines elicited comparable levels of spike-specific antibodies and virus neutralization in mice. Results from a SARS-CoV-2 challenge model in hamsters suggest cross-protective properties of the multiantigenic vaccine against VoC, indicating improved viral clearance with ORFV-S/N, as compared to equal doses of ORFV-S. In a nonhuman primate challenge model, vaccination with the ORFV-S/N vaccine resulted in long-term protection against SARS-CoV-2 infection. These results demonstrate the potential of the ORFV platform for prophylactic vaccination and represent a preclinical development program supporting first-in-man studies with the multiantigenic ORFV vaccine.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Reguzova</LastName><ForeName>Alena</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Immunology, University Hospital Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Müller</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Immunology, University Hospital Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pagallies</LastName><ForeName>Felix</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Immunology, University Hospital Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burri</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Speransa Therapeutics, Bethmannstrasse 8, 60311, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salomon</LastName><ForeName>Ferdinand</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Immunology, University Hospital Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rziha</LastName><ForeName>Hanns-Joachim</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Institute of Immunology, University Hospital Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bittner-Schrader</LastName><ForeName>Zsofia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Institute of Immunology, University Hospital Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verstrepen</LastName><ForeName>Babs E</ForeName><Initials>BE</Initials><Identifier Source="ORCID">0000-0002-4666-0798</Identifier><AffiliationInfo><Affiliation>Department of Virology, Biomedical Primate Research Centre, Lange Kleiweg 161, 2288GJ, Rijswijk, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Viroscience, Erasmus University Medical Center, Dr. Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Böszörményi</LastName><ForeName>Kinga P</ForeName><Initials>KP</Initials><Identifier Source="ORCID">0000-0001-5330-2617</Identifier><AffiliationInfo><Affiliation>Department of Virology, Biomedical Primate Research Centre, Lange Kleiweg 161, 2288GJ, Rijswijk, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verschoor</LastName><ForeName>Ernst J</ForeName><Initials>EJ</Initials><Identifier Source="ORCID">0000-0003-0912-2074</Identifier><AffiliationInfo><Affiliation>Department of Virology, Biomedical Primate Research Centre, Lange Kleiweg 161, 2288GJ, Rijswijk, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhauser</LastName><ForeName>Ingo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of Veterinary Medicine Hannover Foundation, Bünteweg 17, 30559, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elbers</LastName><ForeName>Knut</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Boehringer Ingelheim International GmbH, Binger Strasse 173, 55216, Ingelheim am Rhein, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ViraTherapeutics GmbH, Bundesstraße 27, 6063, Rum, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esen</LastName><ForeName>Meral</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Tropical Medicine, University of Tübingen, Wilhelmstraße 27, 72074, Tübingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Infection Research (DZIF), Partner Site Tübingen; Cluster of Excellence (EXC2124) "Controlling Microbes to Fight Infection", Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manenti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>VisMederi Srl., Strada del Petriccio e Belriguardo 35, 53100, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monti</LastName><ForeName>Martina</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2173-7269</Identifier><AffiliationInfo><Affiliation>VisMederi Srl., Strada del Petriccio e Belriguardo 35, 53100, Siena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rammensee</LastName><ForeName>Hans-Georg</ForeName><Initials>HG</Initials><Identifier Source="ORCID">0000-0003-1614-2647</Identifier><AffiliationInfo><Affiliation>Institute of Immunology, University Hospital Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Derouazi</LastName><ForeName>Madiha</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-9412-9558</Identifier><AffiliationInfo><Affiliation>Speransa Therapeutics, Bethmannstrasse 8, 60311, Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Löffler</LastName><ForeName>Markus W</ForeName><Initials>MW</Initials><Identifier Source="ORCID">0000-0003-2513-1317</Identifier><AffiliationInfo><Affiliation>Institute of Immunology, University Hospital Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany. markus.loeffler@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany. markus.loeffler@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tübingen, University Hospital Tübingen, Otfried-Müller-Str. 4/1, 72076, Tübingen, Germany. markus.loeffler@uni-tuebingen.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Clinical Transfusion Medicine, Otfried-Müller-Str. 4/1, 72076, Tübingen, Germany. markus.loeffler@uni-tuebingen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amann</LastName><ForeName>Ralf</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Immunology, University Hospital Tübingen, Auf der Morgenstelle 15, 72076, Tübingen, Germany. ralf.amann@ifiz.uni-tuebingen.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Vaccines</MedlineTA><NlmUniqueID>101699863</NlmUniqueID><ISSNLinking>2059-0105</ISSNLinking></MedlineJournalInfo><CoiStatement>R.A., M.Mü. and F.S. have ownership interest in Prime Vector Technologies GmbH. R.A. and H.-J.R. are inventors and patent-holders on recombinant ORFV vector (EP16741595, EP15794491). R.A., M.Mü., F.S., A.R. and F.P. are inventors and patent-holders on ORFV-based SARS-CoV-2 vaccines and uses thereof (EP23730776). M.W.L. is an inventor of patents owned by Immatics Biotechnologies unrelated to this present work and has acted as a paid consultant in cancer immunology for Boehringer Ingelheim. M.M. and A.M. are employees of VisMederi Srl. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>23</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39414789</ArticleId><ArticleId IdType="pmc">PMC11484955</ArticleId><ArticleId IdType="doi">10.1038/s41541-024-00981-2</ArticleId><ArticleId IdType="pii">10.1038/s41541-024-00981-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Feikin, D. R. et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet399, 924–944 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8863502</ArticleId><ArticleId IdType="pubmed">35202601</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend, J. P., Hassler, H. B., Sah, P., Galvani, A. P. &amp; Dornburg, A. The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. Proc. Natl Acad. Sci. USA119, e2204336119 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9351502</ArticleId><ArticleId IdType="pubmed">35858382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuertz, K. M. et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. NPJ Vaccines6, 129 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8553838</ArticleId><ArticleId IdType="pubmed">34711815</ArticleId></ArticleIdList></Reference><Reference><Citation>Naranbhai, V. et al. T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell185, 1259 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8969090</ArticleId><ArticleId IdType="pubmed">35364034</ArticleId></ArticleIdList></Reference><Reference><Citation>Geers, D. et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci. Immunol.6, eabj1750 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9268159</ArticleId><ArticleId IdType="pubmed">34035118</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity52, 971–977.e973 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196424</ArticleId><ArticleId IdType="pubmed">32413330</ArticleId></ArticleIdList></Reference><Reference><Citation>Oronsky, B. et al. Nucleocapsid as a next-generation COVID-19 vaccine candidate. Int. J. Infect. Dis.122, 529–530 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250828</ArticleId><ArticleId IdType="pubmed">35788417</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta, N. K., Mazumdar, K. &amp; Gordy, J. T. The nucleocapsid protein of SARS-CoV-2: a target for vaccine development. J. Virol.94, e00647-20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307180</ArticleId><ArticleId IdType="pubmed">32546606</ArticleId></ArticleIdList></Reference><Reference><Citation>Thura, M. et al. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs. Biosci. Rep.41, BSR20211491 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8463655</ArticleId><ArticleId IdType="pubmed">34519332</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, C. K., Hou, M. H., Chang, C. F., Hsiao, C. D. &amp; Huang, T. H. The SARS coronavirus nucleocapsid protein-forms and functions. Antivir. Res.103, 39–50 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113676</ArticleId><ArticleId IdType="pubmed">24418573</ArticleId></ArticleIdList></Reference><Reference><Citation>de Breyne, S. et al. Translational control of coronaviruses. Nucleic Acids Res.48, 12502–12522 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736815</ArticleId><ArticleId IdType="pubmed">33264393</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss, S. R. &amp; Leibowitz, J. L. Coronavirus pathogenesis. Adv. Virus Res.81, 85–164 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7149603</ArticleId><ArticleId IdType="pubmed">22094080</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiuppesi, F. et al. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. iScience25, 104745 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9272674</ArticleId><ArticleId IdType="pubmed">35846380</ArticleId></ArticleIdList></Reference><Reference><Citation>Matchett, W. E. et al. Cutting edge: nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity. J. Immunol.207, 376–379 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8516699</ArticleId><ArticleId IdType="pubmed">34193597</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajnik, R. L. et al. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Sci. Transl. Med.14, eabq1945 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9926941</ArticleId><ArticleId IdType="pubmed">36103514</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia, Q. et al. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 membrane and nucleocapsid proteins protects against severe COVID-19-like disease in hamsters. NPJ Vaccines6, 47 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009914</ArticleId><ArticleId IdType="pubmed">33785745</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiuppesi, F. et al. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. NPJ Vaccines7, 7 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782996</ArticleId><ArticleId IdType="pubmed">35064109</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, W. et al. Nucleocapsid protein of SARS-CoV-2 is a potential target for developing new generation of vaccine. J. Clin. Lab. Anal.36, e24479 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9169192</ArticleId><ArticleId IdType="pubmed">35527696</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangi, T., Class, J., Palacio, N., Richner, J. M. &amp; Penaloza MacMaster, P. Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. Cell Rep.36, 109664 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8367759</ArticleId><ArticleId IdType="pubmed">34450033</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva, E. et al. Immunization with SARS-CoV-2 nucleocapsid protein triggers a pulmonary immune response in rats. PLoS ONE17, e0268434 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9129034</ArticleId><ArticleId IdType="pubmed">35609032</ArticleId></ArticleIdList></Reference><Reference><Citation>Routhu, N. K. et al. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. Sci. Immunol.7, eabo0226 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8995033</ArticleId><ArticleId IdType="pubmed">35357886</ArticleId></ArticleIdList></Reference><Reference><Citation>McCafferty, S. et al. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity. Mol. Ther.30, 2968–2983 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9020838</ArticleId><ArticleId IdType="pubmed">35450821</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiuppesi, F. et al. Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial. Lancet Microbe3, e252–e264 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8906816</ArticleId><ArticleId IdType="pubmed">35287430</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming, S. B., Wise, L. M. &amp; Mercer, A. A. Molecular genetic analysis of orf virus: a poxvirus that has adapted to skin. Viruses7, 1505–1539 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4379583</ArticleId><ArticleId IdType="pubmed">25807056</ArticleId></ArticleIdList></Reference><Reference><Citation>Rziha, H. J. et al. Parapoxviruses: potential alternative vectors for directing the immune response in permissive and non-permissive hosts. J. Biotechnol.73, 235–242 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10486932</ArticleId></ArticleIdList></Reference><Reference><Citation>Buttner, M. &amp; Rziha, H. J. Parapoxviruses: from the lesion to the viral genome. J. Vet. Med. B Infect. Dis. Vet. Public Health49, 7–16 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11911596</ArticleId></ArticleIdList></Reference><Reference><Citation>Rziha, H. J. et al. Genomic characterization of Orf virus strain D1701-V (Parapoxvirus) and development of novel sites for multiple transgene expression. Viruses11, 127 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6409557</ArticleId><ArticleId IdType="pubmed">30704093</ArticleId></ArticleIdList></Reference><Reference><Citation>Amann, R. et al. A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein. J. Virol.87, 1618–1630 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3554190</ArticleId><ArticleId IdType="pubmed">23175365</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohde, J., Amann, R. &amp; Rziha, H. J. New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus. PLoS ONE8, e83802 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869816</ArticleId><ArticleId IdType="pubmed">24376753</ArticleId></ArticleIdList></Reference><Reference><Citation>van Rooij, E. M., Rijsewijk, F. A., Moonen-Leusen, H. W., Bianchi, A. T. &amp; Rziha, H. J. Comparison of different prime-boost regimes with DNA and recombinant Orf virus based vaccines expressing glycoprotein D of pseudorabies virus in pigs. Vaccine28, 1808–1813 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20018271</ArticleId></ArticleIdList></Reference><Reference><Citation>Henkel, M., Planz, O., Fischer, T., Stitz, L. &amp; Rziha, H. J. Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant. J. Virol.79, 314–325 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC538698</ArticleId><ArticleId IdType="pubmed">15596826</ArticleId></ArticleIdList></Reference><Reference><Citation>Metz, C., Haug, V., Muller, M. &amp; Amann, R. Pharmacokinetic and environmental risk assessment of Prime-2-CoV, a non-replicating Orf virus-based vaccine against SARS-CoV-2. Vaccines12, 492 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11126055</ArticleId><ArticleId IdType="pubmed">38793743</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagallies, F., Labisch, J. J., Wronska, M., Pflanz, K. &amp; Amann, R. Efficient and scalable clarification of Orf virus from HEK suspension for vaccine development. Vaccine X18, 100474 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10958475</ArticleId><ArticleId IdType="pubmed">38523620</ArticleId></ArticleIdList></Reference><Reference><Citation>Eilts, F. et al. Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus. Vaccine41, 4731–4742 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37353451</ArticleId></ArticleIdList></Reference><Reference><Citation>Rziha, H. J., Rohde, J. &amp; Amann, R. Generation and selection of Orf virus (ORFV) recombinants. Methods Mol. Biol.1349, 177–200 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26458837</ArticleId></ArticleIdList></Reference><Reference><Citation>Manenti, A. et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples. J. Med. Virol.92, 2096–2104 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267461</ArticleId><ArticleId IdType="pubmed">32383254</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed, L. J. &amp; Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol.27, 493–497 (1938).</Citation></Reference><Reference><Citation>Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill.25, 2000045 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature581, 465–469 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Perera, R. A. et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill.25, 2000421 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189648</ArticleId><ArticleId IdType="pubmed">32347204</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, D. et al. ASC- and caspase-1-deficient C57BL/6 mice do not develop demyelinating disease after infection with Theiler’s murine encephalomyelitis virus. Sci. Rep.13, 10960 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10326010</ArticleId><ArticleId IdType="pubmed">37414913</ArticleId></ArticleIdList></Reference><Reference><Citation>Müller, M., Reguzova, A., Löffler, M. W. &amp; Amann, R. Orf virus-based vectors preferentially target professional antigen-presenting cells, activate the STING pathway and induce strong antigen-specific T cell responses. Front. Immunol.13, 873351 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9124846</ArticleId><ArticleId IdType="pubmed">35615366</ArticleId></ArticleIdList></Reference><Reference><Citation>Reguzova, A. et al. A novel Orf virus D1701-VrV-based dengue virus (DENV) vaccine candidate expressing HLA-specific T cell epitopes: a proof-of-concept study. Biomedicines9, 1862 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8698572</ArticleId><ArticleId IdType="pubmed">34944678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, F. et al. A new coronavirus associated with human respiratory disease in China. Nature579, 265–269 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094943</ArticleId><ArticleId IdType="pubmed">32015508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science367, 1260–1263 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164637</ArticleId><ArticleId IdType="pubmed">32075877</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi, Z. A. et al. Golden Syrian hamster as a model to study cardiovascular complications associated with SARS-CoV-2 infection. Elife11, e73522 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8794466</ArticleId><ArticleId IdType="pubmed">35014610</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med.384, 403–416 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov, D. Y. et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet397, 671–681 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med.383, 2603–2615 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N. Engl. J. Med.384, 2187–2201 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8220996</ArticleId><ArticleId IdType="pubmed">33882225</ArticleId></ArticleIdList></Reference><Reference><Citation>Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet397, 99–111 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7723445</ArticleId><ArticleId IdType="pubmed">33306989</ArticleId></ArticleIdList></Reference><Reference><Citation>Heath, P. T. et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N. Engl. J. Med.385, 1172–1183 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262625</ArticleId><ArticleId IdType="pubmed">34192426</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo, T. et al. Immunological imprinting of the antibody response in COVID-19 patients. Nat. Commun.12, 3781 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8213790</ArticleId><ArticleId IdType="pubmed">34145263</ArticleId></ArticleIdList></Reference><Reference><Citation>Reguzova, A., Ghosh, M., Muller, M., Rziha, H. J. &amp; Amann, R. Orf virus-based vaccine vector D1701-V induces strong CD8+ T cell response against the transgene but not against ORFV-derived epitopes. Vaccines8, 295 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349966</ArticleId><ArticleId IdType="pubmed">32531997</ArticleId></ArticleIdList></Reference><Reference><Citation>Haig, D. M. &amp; Mercer, A. A. Ovine diseases. Orf. Vet. Res.29, 311–326 (1998).</Citation><ArticleIdList><ArticleId IdType="pubmed">9689744</ArticleId></ArticleIdList></Reference><Reference><Citation>Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W. &amp; Mastrobattista, E. Addressing the cold reality of mRNA vaccine stability. J. Pharm. Sci.110, 997–1001 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834447</ArticleId><ArticleId IdType="pubmed">33321139</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni, A. et al. SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19. Cell Host Microbe29, 1076–1092 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8139264</ArticleId><ArticleId IdType="pubmed">34237248</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice, A. et al. Intranasal plus subcutaneous prime vaccination with a dual antigen COVID-19 vaccine elicits T-cell and antibody responses in mice. Sci. Rep.11, 14917 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8295250</ArticleId><ArticleId IdType="pubmed">34290317</ArticleId></ArticleIdList></Reference><Reference><Citation>Gabitzsch, E. et al. Dual-antigen COVID-19 vaccine subcutaneous prime delivery with oral boosts protects NHP against SARS-CoV-2 challenge. Front. Immunol.12, 729837 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8481919</ArticleId><ArticleId IdType="pubmed">34603305</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan, J. F. et al. Simulation of the clinical and pathological manifestations of coronavirus disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin. Infect. Dis.71, 2428–2446 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184405</ArticleId><ArticleId IdType="pubmed">32215622</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Lubbe, J. E. M. et al. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. NPJ Vaccines6, 39 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7979827</ArticleId><ArticleId IdType="pubmed">33741993</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch, S. et al. mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. NPJ Vaccines6, 57 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8052455</ArticleId><ArticleId IdType="pubmed">33863911</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Y. et al. Scalable live-attenuated SARS-CoV-2 vaccine candidate demonstrates preclinical safety and efficacy. Proc. Natl Acad. Sci. USA118, e2102775118 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8307828</ArticleId><ArticleId IdType="pubmed">34193524</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, S. et al. Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters. Nat. Commun.13, 6792 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648440</ArticleId><ArticleId IdType="pubmed">36357440</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Q. Y. et al. LitCovid in 2022: an information resource for the COVID-19 literature. Nucleic Acids Res.51, D1512–D1518 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9825538</ArticleId><ArticleId IdType="pubmed">36350613</ArticleId></ArticleIdList></Reference><Reference><Citation>Caddy, S. L. et al. Viral nucleoprotein antibodies activate TRIM21 and induce T cell immunity. EMBO J.40, e106228 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7917548</ArticleId><ArticleId IdType="pubmed">33258165</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangi, T. et al. Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody. J. Clin. Invest.132, e162282 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9711872</ArticleId><ArticleId IdType="pubmed">36219482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Munoz, A. D., Kosik, I., Holly, J. &amp; Yewdell, J. W. Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity. Sci. Adv.8, eabp9770 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9348789</ArticleId><ArticleId IdType="pubmed">35921414</ArticleId></ArticleIdList></Reference><Reference><Citation>Eser, T. M. et al. Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion. Nat. Commun.14, 2952 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10209201</ArticleId><ArticleId IdType="pubmed">37225706</ArticleId></ArticleIdList></Reference><Reference><Citation>Wussow, F. et al. Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants. NPJ Vaccines8, 41 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10018591</ArticleId><ArticleId IdType="pubmed">36928589</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>